Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6701897 | 0.80 | SCD (0.52) | ALDH1A1LMNAKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL6289333 | 0.71 | LMNA (0.44) | ALDH1A1LMNAKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL6288787 | 0.70 | PTGER4 (0.46) | ALDH1A1SCDMAPTTP53 | |
| SCHEMBL6292734 | 0.70 | LMNA (0.47) | ALDH1A1LMNAKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL6748396 | 0.69 | SMN1; SMN2 (0.43) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6288765 | 0.68 | HPGD (0.47) | ALDH1A1LMNAKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL6292798 | 0.67 | PTGER4 (0.40) | ALDH1A1LMNAKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL6745755 | 0.66 | MAPT (0.47) | LMNASMN1; SMN2THRBMAPTTP53 | |
| SCHEMBL17804027 | 0.66 | SCD (0.45) | ALDH1A1LMNASMN1; SMN2THRBCCR3 | |
| SCHEMBL3043662 | 0.66 | SCD (0.66) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949651-B2 | Fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | LINCOLN FOODSERVICE PRODUCTS INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2004014375-A2 | FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | ALDH1A1 337/4885LMNA 1817/4885KDM4E 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.